Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRTXNASDAQ:DMTKNASDAQ:KDLYNASDAQ:MGRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRTXBiorestorative Therapies$1.70-1.2%$1.74$1.21▼$2.55$12.91M76.75148,734 shs127,304 shsDMTKDermTech$0.19$0.09▼$3.90$3.29M2.481.07 million shs3.66 million shsKDLYKindly MD$14.82-1.8%$10.76$0.65▼$34.77$89.25MN/A2.07 million shs577,305 shsMGRXMangoceuticals$1.97+1.5%$1.89$1.32▼$7.66$10.03M2.75213,330 shs84,915 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRTXBiorestorative Therapies-1.16%-9.57%+7.26%-0.58%-15.84%DMTKDermTech0.00%0.00%0.00%0.00%-54.64%KDLYKindly MD-1.79%+27.76%+6.16%+915.07%+444.85%MGRXMangoceuticals+1.55%-1.99%+30.90%-54.71%-97.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBRTXBiorestorative Therapies3.884 of 5 stars3.55.00.00.03.83.30.6DMTKDermTechN/AN/AN/AN/AN/AN/AN/AN/AKDLYKindly MDN/AN/AN/AN/AN/AN/AN/AN/AMGRXMangoceuticals0.5145 of 5 stars0.03.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRTXBiorestorative Therapies 3.00Buy$18.00958.82% UpsideDMTKDermTech 0.00N/AN/AN/AKDLYKindly MD 0.00N/AN/AN/AMGRXMangoceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRTXBiorestorative Therapies$400K31.88N/AN/A$1.23 per share1.38DMTKDermTech$15.66M0.00N/AN/A$1.67 per share0.00KDLYKindly MD$2.47M36.13N/AN/AN/A∞MGRXMangoceuticals$620K16.43N/AN/A$4.30 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRTXBiorestorative Therapies-$8.98M-$1.47N/AN/AN/A-3,093.61%-129.47%-86.02%8/12/2025 (Estimated)DMTKDermTech-$100.89M-$2.70N/AN/AN/A-572.19%-138.79%-68.96%N/AKDLYKindly MDN/A-$0.77N/A∞N/AN/AN/AN/AN/AMGRXMangoceuticals-$8.71M-$4.64N/A∞N/A-2,191.76%-72.81%-66.58%N/ALatest DMTK, MGRX, BRTX, and KDLY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MGRXMangoceuticalsN/A-$1.29N/A-$1.29N/A$0.11 million5/14/2025Q1 2025BRTXBiorestorative Therapies-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million5/8/2025Q1 2025KDLYKindly MDN/A-$0.17N/A-$0.17N/AN/A3/28/2025Q4 2024KDLYKindly MDN/A-$0.17N/A-$0.17N/A$0.60 million3/27/2025Q4 2024BRTXBiorestorative Therapies-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 million3/20/2025Q4 2024MGRXMangoceuticalsN/A-$1.01N/A-$1.01N/A$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRTXBiorestorative TherapiesN/AN/AN/AN/AN/ADMTKDermTechN/AN/AN/AN/AN/AKDLYKindly MDN/AN/AN/AN/AN/AMGRXMangoceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRTXBiorestorative TherapiesN/A2.242.24DMTKDermTechN/A3.533.46KDLYKindly MDN/A5.435.42MGRXMangoceuticalsN/A0.120.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRTXBiorestorative Therapies69.38%DMTKDermTech20.45%KDLYKindly MDN/AMGRXMangoceuticals56.72%Insider OwnershipCompanyInsider OwnershipBRTXBiorestorative Therapies25.50%DMTKDermTech5.10%KDLYKindly MD50.50%MGRXMangoceuticals16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRTXBiorestorative Therapies77.50 million5.59 millionNot OptionableDMTKDermTech26034.96 million33.18 millionOptionableKDLYKindly MDN/A6.02 million2.96 millionN/AMGRXMangoceuticals35.17 million4.34 millionNot OptionableDMTK, MGRX, BRTX, and KDLY HeadlinesRecent News About These CompaniesMangoceuticals (NASDAQ:MGRX) Trading Up 1.5% - Here's What HappenedJune 19 at 2:15 AM | americanbankingnews.comMangoceuticals Strengthens Position with Equity TransactionsJune 10, 2025 | tipranks.comMangoceuticals files to sell 4.46M shares of common stock by selling shareholdersMay 30, 2025 | msn.comMangoceuticals, Inc.: Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian FluMay 29, 2025 | finanznachrichten.deMangoceuticals, Inc. Reports 100% Survival Rates in Field Studies of MGX-0024 for Poultry Respiratory DiseasesMay 29, 2025 | nasdaq.comMangoceuticals shares results from field studies on MGX-0024May 29, 2025 | finance.yahoo.comMangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian FluMay 27, 2025 | globenewswire.comMangoceuticals, Inc. Terminates Agreements with Key PartnersMay 23, 2025 | tipranks.comArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch MarketApril 28, 2025 | newsfilecorp.comMangoceuticals Enters Wellness Pouch Market, Appoints Tim Corkum To Lead New UnitApril 27, 2025 | nasdaq.comMangoceuticals enters into agreement to acquire assets of Smokeless TechnologyApril 27, 2025 | markets.businessinsider.comCORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch SectorApril 26, 2025 | newsfilecorp.comCORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch SectorApril 26, 2025 | newsfilecorp.comArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch SectorApril 25, 2025 | newsfilecorp.comMangoceuticals Acquires IP to Expand Product LineApril 25, 2025 | tipranks.comMangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch DivisionApril 25, 2025 | globenewswire.comMangoceuticals Is Reengineering the Self-Care Blueprint with Better Personal Health and Wellness SolutionsApril 24, 2025 | finance.yahoo.comCEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health LandscapeApril 22, 2025 | accessnewswire.comMangoceuticals Issues Bonus Shares to LeadershipApril 11, 2025 | tipranks.comMangoceuticals Issues Common Stock in Exchange for PreferredMarch 30, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMTK, MGRX, BRTX, and KDLY Company DescriptionsBiorestorative Therapies NASDAQ:BRTX$1.70 -0.02 (-1.16%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.69 -0.01 (-0.35%) As of 06/18/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.DermTech NASDAQ:DMTKDermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.Kindly MD NASDAQ:KDLY$14.82 -0.27 (-1.79%) As of 06/17/2025Kindly MD, Inc. provides healthcare services. Its services include medication management, behavioral healthcare and alternative treatments. The firm offers evaluation and management, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy. The company was founded by Timothy Pickett in December 2019 and is headquartered in Murray, UT.Mangoceuticals NASDAQ:MGRX$1.97 +0.03 (+1.55%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.97 0.00 (0.00%) As of 06/18/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
